Pharma News

Shanghai Pharma and Russia’s Biocad form joint venture to sell cancer and autoimmune drugs in China

Home/Pharma News | Posted 27/09/2019

Shanghai Pharmaceuticals Holding and Russia’s Biocad Pharmaceutical have agreed to form a joint venture to develop, manufacture and market cancer and autoimmune disease treatments in China.

Sandoz makes deal with Polpharma for natalizumab biosimilar

Home/Pharma News | Posted 20/09/2019

Sandoz, the generics division of Novartis, and Poland-based Polpharma Biologics announced on 3 September 2019 that they had signed a worldwide agreement giving Sandoz commercialization rights to Polpharma’s candidate natalizumab biosimilar (PB006).

Huons enters biosimilar market while private equity firm PAG invests in Hisun BioRay

Home/Pharma News | Posted 13/09/2019

Huons has announced its plans to enter the biosimilar market, and private equity firm PAG has acquired a controlling interesting in Hisun Pharmaceutical’s biopharmaceutical subsidiary, Hisun BioRay.

Alvotech and Cipla Gulf partnership announced

Home/Pharma News | Posted 30/08/2019

On 29 July 2019, pharmaceutical companies Alvotech and Cipla Gulf announced that they have entered into an exclusive partnership for the commercialization of an adalimumab biosimilar (AVT02), in a selection of emerging markets.

Agreement between Hikma and Civica to reduce US generic drug shortages

Home/Pharma News | Posted 23/08/2019

Hikma Pharmaceuticals Plc and Civica Rx announced a five-year agreement on 23 July 2019. Under the agreement, Hikma will manufacture and supply 14 essential sterile injectable medications for Civica. It will use Hikma's abbreviated new drug applications (ANDAs) and Civica's labelling and National Drug Code (NDC). The full list of medications included in the agreement, that are often in short supply in US hospitals, will be publicly announced in the near future. Initial shipments are expected by the end of 2019.

WHO essential medicines list: new lung cancer medicines rejected

Home/Pharma News | Posted 16/08/2019

The World Health Organization’s (WHO) list of ‘essential medicines’, received a biennial update on 9 July 2019. It added 28 drugs but left out several new treatments for lung cancer.

Prestige and Pharmapark make deal for trastuzumab biosimilar

Home/Pharma News | Posted 09/08/2019

Singapore-based Prestige BioPharma (Prestige) and Russia-based Pharmapark announced on 8 July 2019 that they had signed an exclusive partnership and supply agreement for Prestige’s candidate trastuzumab biosimilar (HD201) in Russia.

Celltrion and Nan Fung Group form joint venture for copy biologicals in China

Home/Pharma News | Posted 02/08/2019

South Korean biosimilars firm Celltrion and Hong Kong-based Nan Fung Group announced on 18 July 2019 that the two companies had formed a joint venture, Vcell Healthcare, with the aim of developing and commercializing copy biologicals in China.

STADA and Xbrane strengthen biosimilars collaboration

Home/Pharma News | Posted 19/07/2019

German generics giant Stada Arzneimittel (Stada) and Swedish biotech company Xbrane Bioscience (Xbrane) announced on 31 May 2019 that they have expanded their strategic biosimilar development partnership.